Mavromoustakos T, Zervou M, Zoumpoulakis P, Kyrikou I, Benetis N P, Polevaya L, Roumelioti P, Giatas N, Zoga A, Minakakis P Moutevelis, Kolocouris A, Vlahakos D, Grdadolnik S Golic, Matsoukas J
Institute of Organic and Pharmaceutical Chemistry, National Hellenic Research Foundation, Athens, Greece.
Curr Top Med Chem. 2004;4(4):385-401. doi: 10.2174/1568026043451302.
Peptidomimitism is applied to the medicinal chemistry in order to synthesize drugs that devoid of the disadvantages of peptides. AT1 antagonists constitute a new generation of drugs for the treatment of hypertension designed and synthesized to mimic the C-terminal segment of Angiotensin II and to block its binding action on AT1 receptor. An effort was made to understand the molecular basis of hypertension by studying the conformational analysis of Ang II and its derivatives as well as the AT1 antagonists belonging to SARTANs class of molecules. Such studies offer the possibility to reveal the stereoelectronic factors responsible for bioactivity of AT1 antagonists and to design and synthesize new analogs. An example will be given which proves that drugs with better pharmacological and financial profiles may arise based on this rational design.
拟肽学应用于药物化学领域,旨在合成没有肽类缺点的药物。AT1拮抗剂是新一代用于治疗高血压的药物,其设计和合成旨在模拟血管紧张素II的C末端片段,并阻断其对AT1受体的结合作用。通过研究血管紧张素II及其衍生物以及属于沙坦类分子的AT1拮抗剂的构象分析,努力了解高血压的分子基础。此类研究为揭示负责AT1拮抗剂生物活性的立体电子因素以及设计和合成新类似物提供了可能性。将给出一个例子,证明基于这种合理设计可能会产生具有更好药理学和经济效益的药物。